140 related articles for article (PubMed ID: 32048329)
1. Real-world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco-Israeli collaborative myeloma working group.
Katodritou E; Kastritis E; Gatt M; Cohen YC; Avivi I; Pouli A; Lalayianni C; Lavi N; Delimpasis S; Kyrtsonis MC; Michael M; Suriu C; Miri Z; Tzafarti K; Vadikoliou C; Maltezas D; Zikos P; Ganzel C; Vaxman Y; Aviv A; Christoforidou A; Gavriatopoulou M; Shaulov A; Verrou E; Papanota AM; Fakinos G; Gkioka AI; Palaska V; Triantafyllou T; Konstantinidou P; Anagnostopoulos A; Terpos E; Dimopoulos MA
Am J Hematol; 2020 May; 95(5):465-471. PubMed ID: 32048329
[TBL] [Abstract][Full Text] [Related]
2. [Clinical characteristics and prognosis of 46 patients with macrofocal multiple myeloma].
Yan WW; Fan HS; Xu JY; Liu JH; Du CX; Deng SH; Sui WW; Xu Y; Qiu LG; An G
Zhonghua Nei Ke Za Zhi; 2022 Jul; 61(7):801-805. PubMed ID: 35764565
[TBL] [Abstract][Full Text] [Related]
3. Macrofocal multiple myeloma in young patients: a distinct entity with favorable prognosis.
Dimopoulos MA; Pouli A; Anagnostopoulos A; Repoussis P; Symeonidis A; Terpos E; Delimbasi S; Tsolakis F; Economopoulos T; Zervas C
Leuk Lymphoma; 2006 Aug; 47(8):1553-6. PubMed ID: 16966266
[TBL] [Abstract][Full Text] [Related]
4. Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
Cohen YC; Magen H; Lavi N; Gatt ME; Chubar E; Horowitz N; Kreiniz N; Tadmor T; Trestman S; Vitkon R; Rouvio O; Shvetz O; Shaulov A; Ziv-Baran T; Avivi I
Ann Hematol; 2020 Jun; 99(6):1273-1281. PubMed ID: 32193630
[TBL] [Abstract][Full Text] [Related]
5. Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients.
Katodritou E; Terpos E; Symeonidis AS; Pouli A; Kelaidi C; Kyrtsonis MC; Kotsopoulou M; Delimpasi S; Christoforidou A; Giannakoulas N; Viniou NA; Stefanoudaki E; Hadjiaggelidou C; Christoulas D; Verrou E; Gastari V; Papadaki S; Polychronidou G; Papadopoulou A; Giannopoulou E; Kastritis E; Kouraklis A; Konstantinidou P; Anagnostopoulos A; Zervas K; Dimopoulos MA
Am J Hematol; 2014 Aug; 89(8):803-8. PubMed ID: 24757085
[TBL] [Abstract][Full Text] [Related]
6. Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry.
Blimark CH; Turesson I; Genell A; Ahlberg L; Björkstrand B; Carlson K; Forsberg K; Juliusson G; Linder O; Mellqvist UH; Nahi H; Kristinsson SY;
Haematologica; 2018 Mar; 103(3):506-513. PubMed ID: 29217784
[TBL] [Abstract][Full Text] [Related]
7. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry.
Alegre A; Granda A; Martínez-Chamorro C; Díaz-Mediavilla J; Martínez R; García-Laraña J; Lahuerta JJ; Sureda A; Bladé J; de la Rubia J; Fernández-Rañada JM; San Miguel J; ; ;
Haematologica; 2002 Jun; 87(6):609-14. PubMed ID: 12031917
[TBL] [Abstract][Full Text] [Related]
8. The treatment outcome of multiple myeloma patients ineligible for hematopoietic transplantation--a single institutional experience in Taiwan.
Huang TC; Chen JH; Wu YY; Chang PY; Dai MS; Chao TY; Kao WY; Chen YC; Ho CL
Ann Hematol; 2015 Jan; 94(1):107-15. PubMed ID: 25047657
[TBL] [Abstract][Full Text] [Related]
9. Autologous stem cell transplantation for multiple myeloma: Long-term results.
Kumar L; Boya RR; Pai R; Harish P; Mookerjee A; Sainath B; Patekar MB; Sahoo RK; Malik PS; Sharma OD; Gupta R
Natl Med J India; 2016; 29(4):192-199. PubMed ID: 28050994
[TBL] [Abstract][Full Text] [Related]
10. Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents.
Zagouri F; Kastritis E; Symeonidis AS; Giannakoulas N; Katodritou E; Delimpasi S; Repousis P; Terpos E; Dimopoulos MA;
Eur J Haematol; 2014 Apr; 92(4):308-12. PubMed ID: 24460646
[TBL] [Abstract][Full Text] [Related]
11. Risk of adverse events associated with front-line anti-myeloma treatment in Medicare patients with multiple myeloma.
Chen Y; Lairson DR; Chan W; Du XL
Ann Hematol; 2018 May; 97(5):851-863. PubMed ID: 29333596
[TBL] [Abstract][Full Text] [Related]
12. Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period.
Terpos E; Ntanasis-Stathopoulos I; Roussou M; Kanellias N; Fotiou D; Migkou M; Eleutherakis-Papaiakovou E; Gavriatopoulou M; Kastritis E; Dimopoulos MA
Ann Hematol; 2020 Jun; 99(6):1257-1264. PubMed ID: 32382768
[TBL] [Abstract][Full Text] [Related]
13. Comparison of outcomes after autologous stem cell transplantation between myeloma patients with skeletal and soft tissue plasmacytoma.
Shin HJ; Kim K; Lee JW; Song MK; Lee JJ; Lee HS; Lee WS; Kim SJ; Chung JS
Eur J Haematol; 2014 Nov; 93(5):414-21. PubMed ID: 24813053
[TBL] [Abstract][Full Text] [Related]
14. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
15. Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patients.
Avivi I; Cohen YC; Suska A; Shragai T; Mikala G; Garderet L; Seny GM; Glickman S; Jayabalan DS; Niesvizky R; Gozzetti A; Wiśniewska-Piąty K; Waszczuk-Gajda A; Usnarska-Zubkiewicz L; Hus I; Guzicka R; Radocha J; Milunovic V; Davila J; Gentile M; Castillo JJ; Jurczyszyn A
Am J Hematol; 2019 Oct; 94(10):1132-1140. PubMed ID: 31334859
[TBL] [Abstract][Full Text] [Related]
16. Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group.
Katodritou E; Terpos E; Delimpasi S; Kotsopoulou M; Michalis E; Vadikolia C; Kyrtsonis MC; Symeonidis A; Giannakoulas N; Vadikolia C; Michael M; Kalpadakis C; Gougopoulou T; Prokopiou C; Kaiafa G; Christoulas D; Gavriatopoulou M; Giannopoulou E; Labropoulou V; Verrou E; Kastritis E; Konstantinidou P; Anagnostopoulos A; Dimopoulos MA
Blood Cancer J; 2018 Mar; 8(3):31. PubMed ID: 29523783
[TBL] [Abstract][Full Text] [Related]
17. High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents.
Terpos E; Katodritou E; Roussou M; Pouli A; Michalis E; Delimpasi S; Parcharidou A; Kartasis Z; Zomas A; Symeonidis A; Viniou NA; Anagnostopoulos N; Economopoulos T; Zervas K; Dimopoulos MA;
Eur J Haematol; 2010 Aug; 85(2):114-9. PubMed ID: 20477863
[TBL] [Abstract][Full Text] [Related]
18. Impact of increased access to novel agents on the survival of multiple myeloma patients treated at a single New Zealand centre.
Hock BD; Mulholland KS; Ganly P; McKenzie JL; Pearson JF; MacPherson SA
Intern Med J; 2019 May; 49(5):598-606. PubMed ID: 30411451
[TBL] [Abstract][Full Text] [Related]
19. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.
Veltri LW; Milton DR; Delgado R; Shah N; Patel K; Nieto Y; Kebriaei P; Popat UR; Parmar S; Oran B; Ciurea S; Hosing C; Lee HC; Manasanch E; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH; Bashir Q
Cancer; 2017 Sep; 123(18):3568-3575. PubMed ID: 28513828
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.
García de Veas Silva JL; Bermudo Guitarte C; Menéndez Valladares P; Rojas Noboa JC; Kestler K; Duro Millán R
PLoS One; 2016; 11(11):e0166841. PubMed ID: 27893836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
